白细胞介素1受体拮抗剂
细胞因子
癌症研究
头颈部鳞状细胞癌
炎症
鳞癌
医学
受体拮抗剂
癌
受体
免疫学
敌手
生物
病理
内科学
癌症
头颈部癌
作者
Yujie Ding,Jie Yi,Jinxin Wang,Zhenfeng Sun
出处
期刊:Heliyon
[Elsevier]
日期:2023-04-01
卷期号:9 (4): e14960-e14960
被引量:2
标识
DOI:10.1016/j.heliyon.2023.e14960
摘要
Inflammation, especially chronic inflammation, is closely linked to tumor development. As essential chronic inflammatory cytokines, the interleukin family plays a key role in inflammatory infections and malignancies. The interleukin-1 (IL-1) receptor antagonist (IL1RA), as a naturally occurring receptor antagonist, is the first discovered and can compete with IL-1 in binding to the receptor. Recent studies have revealed the association of the polymorphisms in IL1RA with an increased risk of squamous cell carcinomas (SCCs), including squamous cell carcinoma of the head and neck (SCCHN), cervical squamous cell carcinoma, cutaneous squamous cell carcinoma (cSCC), esophageal squamous cell carcinoma (ESCC), and bronchus squamous cell carcinoma. Here, we reviewed the antitumor potential of IL1RA as an IL-1-targeted inhibitor.
科研通智能强力驱动
Strongly Powered by AbleSci AI